Sattva S Neelapu, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, outlines updates in CAR T-cell therapies in lymphoma. Specifically discussed is the CAR-T construct, axicabtagene ciloleucel, which is approved for the treatment of relapsed/refractory large B-cell lymphoma on the basis of the ZUMA-1 trial (NCT02348216), as well as the outcomes of the JULIET (NCT02445248) & TRANSCEND (NCT02631044) studies. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

свернуть